COVID-19-related myocarditis and cholinergic anti-inflammatory pathways

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weike, Liu, Zhendong, Li, Yue-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Cardiology. Publishing services by Elsevier B.V. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722500/
https://www.ncbi.nlm.nih.gov/pubmed/33301863
http://dx.doi.org/10.1016/j.hjc.2020.12.004
_version_ 1783620166460899328
author Liu, Weike
Liu, Zhendong
Li, Yue-Chun
author_facet Liu, Weike
Liu, Zhendong
Li, Yue-Chun
author_sort Liu, Weike
collection PubMed
description Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis.
format Online
Article
Text
id pubmed-7722500
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hellenic Society of Cardiology. Publishing services by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-77225002020-12-10 COVID-19-related myocarditis and cholinergic anti-inflammatory pathways Liu, Weike Liu, Zhendong Li, Yue-Chun Hellenic J Cardiol Review Article Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2, is currently in a pandemic outbreak and has become a global health issue. In addition to the primarily involvement of the respiratory system, myocarditis is considered an important and fatal lesion in patients with COVID-19. However, effective therapeutic methods are currently lacking. The cholinergic anti-inflammatory pathway (CAP) has been demonstrated to suppress pro-inflammatory cytokine production and control inflammation in sepsis and other medical conditions. Therefore, the CAP may be a potential and effective therapeutic method for COVID-19-related myocarditis. This article reviews the relationship between COVID-19-related myocarditis and the CAP and discusses the CAP as a potential therapeutic modality in the treatment of COVID-19-related myocarditis. Hellenic Society of Cardiology. Publishing services by Elsevier B.V. 2021 2020-12-08 /pmc/articles/PMC7722500/ /pubmed/33301863 http://dx.doi.org/10.1016/j.hjc.2020.12.004 Text en © 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Liu, Weike
Liu, Zhendong
Li, Yue-Chun
COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title_full COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title_fullStr COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title_full_unstemmed COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title_short COVID-19-related myocarditis and cholinergic anti-inflammatory pathways
title_sort covid-19-related myocarditis and cholinergic anti-inflammatory pathways
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722500/
https://www.ncbi.nlm.nih.gov/pubmed/33301863
http://dx.doi.org/10.1016/j.hjc.2020.12.004
work_keys_str_mv AT liuweike covid19relatedmyocarditisandcholinergicantiinflammatorypathways
AT liuzhendong covid19relatedmyocarditisandcholinergicantiinflammatorypathways
AT liyuechun covid19relatedmyocarditisandcholinergicantiinflammatorypathways

Ejemplares similares